

Resting State Cortical Electroencephalographic Rhythms and White Matter Vascular Lesions in Subjects with Alzheimer's Disease: An Italian Multicenter Study

Claudio Babiloni^{a,b,*}, Roberta Lizio^c, Filippo Carducci^d, Fabrizio Vecchio^e, Alberto Redolfi^f,
Silvia Marino^g, Gioacchino Tedeschi^{h,i}, Patrizia Montella^h, Antonio Guizzaro^h, Fabrizio Esposito^j,
Alessandro Bozzao^k, Franco Giubilei^k, Francesco Orzi^k, Carlo C. Quattrocchi^l, Andrea Soricelli^m,
Elena Salvatore^m, Annalisa Baglieri^g, Placido Bramanti^g, Marina Boccardi^f, Raffaele Ferriⁿ,
Filomena Cosentinoⁿ, Michelangelo Ferraraⁿ, Ciro Mundi^o, Gianpaolo Grilli^o, Silvia Pugliese^d,
Gianluca Gerardi^d, Laura Parisi^e, Fabrizio Vernieri^l, Antonio I. Triggiani^a, Jan T. Pedersen^p,
Hans-Göran Hårdemark^q, Paolo M. Rossini^{b,r} and Giovanni B. Frisoni^f

^aDepartment of Biomedical Sciences, University of Foggia, Foggia, Italy

^bDepartment of Imaging, SAN RAFFAELE Cassino, Italy

^cIRCCS San Raffaele Pisana, Rome, Italy

^dLaboratory of Computational Neuroanatomy, Department of Physiology and Pharmacology,
University of Rome "Sapienza", Rome, Italy

^eA.Fa.R., Dip. Neurosci. Osp. FBF; Isola Tiberina, Rome, Italy

^fIRCCS "S. Giovanni di Dio-F.B.F.", Brescia, Italy

^gIRCCS Centro Neurolesi "Bonino-Pulejo" – Messina, Italy

^hDepartment of Neurological Sciences, Second University of Naples, Naples, Italy

ⁱNeurological Institute for Diagnosis and Care "Hermitage Capodimonte", Naples, Italy

^jDepartment of Neuroscience, University of Naples "Federico II", Naples, Italy

^kAzienda Ospedaliera Sant'Andrea Università di Roma "Sapienza", Roma, Italy

^lIRCCS "Ospedale Pediatrico Bambino Gesù", Roma, Italy

^mFondazione SDN per la Ricerca e l'Alta Formazione in Diagnostica Nucleare, IRCCS Naples, Italy

ⁿIRCCS Oasi, Troina (Enna), Italy

^oDepartment of Neuroscience, Ospedali Riuniti di Foggia, Foggia, Italy

^pSection head, Bioinformatics, H. Lundbeck A/S, Valby, Denmark

^qAstrazeneca, Stockholm, Sverige

^rNeurol. University "Campus Biomedico" Rome, Italy

Accepted 9 April 2011

*Correspondence to: Prof. Claudio Babiloni, PhD, Department of Biomedical Sciences, University of Foggia, Viale Pinto 7, Foggia I-71100, Italy. Tel. and Fax: +39 0881 713276 (1716); E-mail: c.babiloni@unifg.it.

Abstract. Resting state electroencephalographic (EEG) rhythms do not deteriorate with the increase of white matter vascular lesion in amnesic mild cognitive impairment (MCI) subjects [1], although white matter is impaired along Alzheimer's disease (AD). Here we tested whether this is true even in AD subjects. Closed-eye resting state EEG data were recorded in 40 healthy elderly (Nold), 96 amnesic MCI, and 83 AD subjects. White matter vascular lesions were indexed by magnetic resonance imaging recorded in the MCI and AD subjects (about 42% of cases following ADNI standards). The MCI subjects were divided into two sub-groups based on the median of the white matter lesion, namely MCI+ (people with highest vascular load; $n = 48$) and MCI- (people with lowest vascular load; $n = 48$). The same was true for the AD subjects (AD+, $n = 42$; AD-, $n = 41$). EEG rhythms of interest were delta (2–4 Hz), theta (4–8 Hz), alpha1 (8–10.5 Hz), alpha2 (10.5–13 Hz), beta1 (13–20 Hz), beta2 (20–30 Hz), and gamma (30–40 Hz). LORETA software estimated cortical EEG sources. When compared to Nold group, MCI and AD groups showed well known abnormalities of delta and alpha sources. Furthermore, amplitude of occipital, temporal, and limbic alpha 1 sources were higher in MCI+ than MCI- group. As a novelty, amplitude of occipital delta sources was lower in AD+ than AD- group. Furthermore, central, parietal, occipital, temporal, and limbic alpha sources were higher in amplitude in AD+ than AD- group. Amplitude of these sources was correlated to global cognitive status (i.e., Mini Mental State Evaluation score). These results suggest that in amnesic MCI and AD subjects, resting state posterior delta and alpha EEG rhythms do not deteriorate with the increase of white-matter vascular lesion. These rhythms might be more sensitive to AD neurodegenerative processes and cognitive status rather than to concomitant lesions to white matter.

Keywords: Alzheimer's disease, Alzheimer's disease neuroimaging initiative, amnesic mild cognitive impairment, electroencephalographic rhythms, low resolution brain electromagnetic tomography, magnetic resonance imaging, resting state, white matter vascular lesion

INTRODUCTION

Previous studies in Alzheimer's disease (AD) and amnesic mild cognitive impairment (MCI) subjects have shown that resting state closed-eye EEG rhythms may be promising markers of disease when evaluated by quantitative methods. When compared to normal elderly (Nold) subjects, AD patients have been characterized by high power of delta (0–4 Hz) and theta (4–7 Hz) rhythms, and low power of posterior alpha (8–12 Hz) and/or beta (13–30 Hz) rhythms [2–8]. In line with the “transition” hypothesis, amnesic MCI subjects have displayed increased theta power [9–11] as well as decreased alpha power [4, 8, 10–15]. Furthermore, power of resting state alpha rhythms in amnesic MCI subjects has been found to be intermediate with respect to that of Nold and AD subjects [6, 12, 14].

A bulk of previous evidence indicates that power of resting state eyes closed EEG rhythms reflect neurodegenerative processes in amnesic MCI and AD subjects [4, 8, 9, 12, 14, 16]. First, in MCI and AD subjects, abnormalities of EEG rhythms were associated to typical signs of neurodegeneration such as hippocampal atrophy [17] and impairment of the cholinergic tracts from basal forebrain to cerebral cortex [17, 18]. Second, these abnormalities were also associated to altered regional cerebral blood flow/metabolism and to impaired global cognitive function in MCI or AD subjects [1, 6, 14, 19–21]. Third, decrement of pos-

terior alpha power showed peculiar features in AD subjects when compared to cerebrovascular dementia subjects with similar cognitive impairment [7]. Fourth, posterior alpha power was relatively preserved in amnesic MCI subjects in whom cognitive decline was mainly explained by white-matter vascular lesion, thus suggesting that these rhythms are less affected by diffuse white matter vascular lesions than parallel neurodegenerative processes [1, 23]. This hypothesis is in line with recent evidence showing that there were fewer neurodegenerative lesions in AD patients with vascular lesions than in those without vascular lesions, suggesting that neurodegenerative and cerebrovascular lesions act as additive/synergistic causes of AD [24–26]. On the other hand, several field studies have reported some interactions between AD and cerebrovascular function. Clinical and cognitive status of AD patients was in part explained by amyloid angiopathy of small vessels [27]. Furthermore, AD patients carrying ApoE4 allele as a genetic risk of AD presented an increment of intima-media thickness values with respect to non-carriers and cerebrovascular dementia patients [28]. Finally, evolution of cognitive function in AD was unfavorable as a function of impaired cerebral vasomotor reactivity [29]. Keeping in mind these data and considerations, current evidence suggests that cerebrovascular dysfunction precedes and accompanies cognitive dysfunction and AD neurodegeneration, although its impact on the abnormalities of resting state

Table 1

Demographic and clinical data of healthy elderly (Nold), mild cognitive impairment (MCI), and mild Alzheimer's disease (AD) subjects

	Subjects (n)	Gender (M/F)	Age (years)	MMSE	IAF (Hz)	IADL	CDR
Nold	40	22/18	72.1 ± (1.0)	27.7 ± (0.2 SE)	9.3 ± (0.2)	–	–
MCI	96	32/64	71.4 ± (1.0)	25.9 ± (0.3 SE)	9.5 ± (0.1)	2.3 (±0.1 SE)	0.3 (±0.06 SE)
AD	83	25/58	69.8 ± (0.8)	19.6 ± (0.5 SE)	8.8 ± (0.2)	4.5 (±0.3 SE)	1.0 (±0.1 SE)

EEG rhythms in AD might be negligible. To address to this issue, the present study tested the hypothesis that in both amnesic MCI and AD subjects, posterior resting state EEG rhythms do not deteriorate with the increase of white-matter vascular lesion, according to the idea that these rhythms are less affected by such vascular than neurodegenerative processes.

METHODS

Subjects

In this study, 96 amnesic MCI subjects and 83 AD patients were recruited. Furthermore, 40 cognitively intact elderly (Nold) subjects were selected as a control group. The Nold subjects globally matched the personal variables of the MCI and AD subjects. Table 1 reports demographic and clinical data of the AD, amnesic MCI, and Nold groups.

The study was approved by the local Institutional ethics committee, and follows prescriptions of the Good Clinical Practice (GCP); informed and overt consent of subjects or subjects' legal representatives, in line with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and the standards established by the Author's Institutional Review Board.

Diagnostic criteria

The present inclusion and exclusion criteria for amnesic MCI subjects were based on international standards [30–39]. Summarizing, the inclusion criteria were as follows: (i) objective memory impairment on ADNI neuropsychological evaluation probing cognitive performance in the domains of memory, language, executive function/attention, etc; (ii) normal activities of daily living as documented by the history and evidence of independent living; and (iii) clinical dementia rating score of 0.5.

The exclusion criteria included: (i) mild dementia of the AD type, as diagnosed by standard protocols including NINCDS-ADRDA [40] and DSM-IV; (ii) evidence (including magnetic resonance imag-

ing – MRI – procedures) of concomitant cerebral impairment such as frontotemporal degeneration, cerebrovascular disease with large vascular lacunar lesions in gray or white matter, and reversible cognitive impairment (including pseudo-depressive dementia); (iii) marked fluctuations in cognitive performance compatible with Lewy body dementia and/or features of mixed cognitive impairment including cerebrovascular disease (particular attention was devoted to this point given the working hypothesis focused on cognitive stability in MCI subjects); (iv) evidence of concomitant extra-pyramidal symptoms; (v) clinical and indirect evidence of depression as revealed by the Geriatric Depression Scale (GDS; [41]) scores >14; (vi) other psychiatric diseases, epilepsy, drug addiction, alcohol dependence (as revealed by a psychiatric interview) and use of psychoactive drugs including acetylcholinesterase inhibitors or other drugs enhancing brain cognitive functions; and (vii) current or previous uncontrolled or complicated systemic diseases (including diabetes mellitus) or traumatic brain injuries.

Probable AD was diagnosed according to NINCDS-ADRDA [40] and DSM IV criteria. The recruited AD patients underwent general medical, neurological, neuropsychological, and psychiatric assessments. Patients were rated with a number of standardized diagnostic and severity instruments that included Mini Mental State Evaluation (MMSE; [42]), Clinical Dementia Rating Scale (CDR; [43]), GDS [41], Hachinski Ischemic Score (HIS, [44]), and Instrumental Activities of Daily Living scale (IADL, [45]). Neuroimaging diagnostic procedures (MRI) and complete laboratory analyses were carried out to exclude other causes of progressive or reversible dementias. Exclusion criteria included any evidence of (i) frontotemporal dementia, diagnosed according to current criteria [46], (ii) MRI of cerebrovascular disease with large vascular lacunar lesions in gray or white matter (iii) vascular dementia, diagnosed according to NINDS-AIREN criteria [47], (iv) extra-pyramidal syndromes, (iv) reversible dementias (including pseudodementia of depression); and (v) Lewy body dementia, according to the criteria by [48].

The present Nold subjects were recruited mostly from non-consanguineous patients' relatives. All Nold subjects underwent physical and neurological examinations as well as cognitive screening (including MMSE and GDS). Subjects affected by chronic systemic illnesses, those receiving psychoactive drugs, or with a history of neurological or psychiatric disease were excluded. All Nold subjects had a GDS score lower than 14 (no depression).

Magnetic Resonance Imaging (MRI)

Three-D proton density (PD), T1- and T2-weighted volumetric MRIs were recorded by the clinical units of the present Italian multi-centric study (University of Foggia-Ospedali Riuniti di Foggia; San Raffaele Cassino; Isola Tiberina Fatebenefratelli Hospital, Rome; IRCCS Fatebenefratelli Brescia; IRCCS Centro Neurolesi, Messina; Azienda Ospedaliera Sant'Andrea University of Rome "Sapienza"; University of Naples "Federico II"; Second University of Naples; University "Campus Biomedico" Rome; IRCCS and Fondazione SDN Naples; IRCCS Oasi, Troina). Some of these units (IRCCS Centro Neurolesi "Bonino-Pulejo", Messina; Azienda Ospedaliera Sant'Andrea University of Rome "Sapienza"; University of Naples "Federico II"; Second University of Naples; University "Campus Biomedico" Rome; IRCCS and Fondazione SDN Naples; IRCCS Oasi, Troina) collected the MRIs following the ADNI protocol (<http://www.adni-info.org/>). In total, about 42% of the whole dataset was collected according to the ADNI project.

Analysis of the 3-D PD, T1-, and T2-weighted volumetric MRIs was centralized at University of Rome "Sapienza". The MRIs were visually inspected to verify the absence of structural abnormalities or technical artifacts. Afterwards, they were given as an input to Expectation-Maximization Segmentation (EMS) software, which is an SPM99 tool (Wellcome Dept. Cogn. Neurol., London; <http://www.fil.ion.ucl.ac.uk/spm>) running under MATLAB 7.0 (MathWorks, Natick, MA). On the whole, the EMS tool performs (i) an automated, atlas-based classification of brain tissue from 3-D PD, T1- and T2-weighted volumetric MRIs, (ii) builds a stochastic individual model of "normal" tissue intensity at voxel level on the basis of all MRIs, (iii) detects voxels with "vascular lesion" by the computation of the Mahalanobis distance. In detail, individual MRIs were corrected for field inhomogeneities and coregistered each other. The coregistered MRIs were normalized to the SPM99 T1 template, which allowed the classification of the voxels into three compartments

including gray matter, white matter or cerebral-spinal fluid. Afterwards, the EMS tool estimated the parameters of a stochastic model of tissue intensity for "normal" brain MRIs in each individual normalized dataset. Tissue intensities for the "normal" brain model were represented with a 3-classes (i.e., gray matter, white matter, and cerebral-spinal fluid) finite multivariate Gaussian mixture. All MRI sequences (i.e., 3-D PD, T1-, and T2-weighted) were used to create a multidimensional feature space, in order to benefit of the specific inherent information of each sequence. These sequences were iteratively classified into a small number of Gaussian distributions. During this iterative process, the EMS tool rejected voxels that exceed a predefined Mahalanobis distance to each of the Gaussians, and updated the model parameters only based on non-rejected voxels [49]. Vascular lesion of white matter was defined as the amount of voxels classified as affected by vascular lesion and rejected from the stochastic model of "normal brain", according to the mentioned Mahalanobis distance. In this framework, the use of Markov random fields (MRF) discouraged a voxel to be classified as brain lesion in the absence of neighboring white matter.

Of note, the EMS tool implements an automated procedure that requires only the Mahalanobis distance threshold parameter (k) to be computed on the basis of a variable defined by the experiment; namely, the parameter k determined the significance level at which voxels are considered as model outliers. An appropriate k value had to be chosen in advance by means of an experimentally tuned procedure, because of the choice of k significantly affects the quality of the brain lesion segmentation [49, 50]. The optimal value of the parameter k was identified on 36 MRI individual datasets. The MRI segmentations were obtained with the automatic tool varying the values of k from 3.0 to 5.0 with steps of 0.5. The results were correlated to those of the MRI segmentation performed by our expert neuroradiologists. The highest correlation was obtained with parameter k equal to 4.0 (Pearson $r=0.7$; $p=0.001$), which is exactly the threshold value suggested by the researcher who developed the EMS tool for the detection of vascular lesions in multiple sclerosis patients (<http://www.medicalimagecomputing.com>).

Based on the above procedure for the estimation of white-matter vascular lesions, the MCI subjects were divided into two sub-groups. The median of the white matter lesion was used as the criterion of the definition of MCI people with highest vascular load or MCI+ (≥ 4960 voxels; mean of 7479 voxels \pm 483 standard error, SE; $n=48$) and of MCI people with

221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272

Table 2

Demographic and clinical data of the following sub-groups: AD with low degree of white-matter lesion (AD−, normalized white-matter vascular lesions <3430); AD with high degree of white-matter lesion (AD+, normalized white-matter vascular lesions ≥3430); MCI with low degree of white-matter lesion (MCI−, normalized white-matter vascular lesions <4960) and MCI with high degree of white-matter lesion (MCI+, normalized white-matter vascular lesions ≥4960)

	Subjects (n)	Gender (M/F)	Age (years)	MMSE	IAF (Hz)	White matter vascular lesion (voxels)
MCI+	48	16/32	69.6 ± (1.2 SE)	26.5 ± (0.4 SE)	9.6 ± (0.2 SE)	7479 ± (483 SE)
MCI−	48	16/32	70.1 ± (1.0 SE)	25.4 ± (0.4 SE)	9.3 ± (0.2 SE)	3332 ± (179 SE)
AD+	42	13/29	72.2 ± (1.2 SE)	21.0 ± (0.6 SE)	8.9 ± (0.2 SE)	8744 ± (1295 SE)
AD−	41	12/29	70.6 ± (1.5 SE)	18.4 ± (0.8 SE)	8.7 ± (0.3 SE)	2298 ± (107 SE)

lowest vascular load or MCI− (<4960 voxels; mean of 3332 voxels ± 179 SE; $n=48$). The same criterion based on the median of the white matter lesion was used to divide AD subjects into the sub-groups of AD+ (≥3430 voxels; mean of 8744 voxels ± 1295 SE; $n=42$) and AD− (<3430 voxels; mean of 2298 voxels ± 107 SE; $n=41$). Table 2 reports demographic and clinical data of the AD−, AD+, MCI−, and MCI+ sub-groups.

EEG recordings

Resting state eyes closed EEG data were recorded (0.3–70 Hz bandpass) from 19 electrodes positioned according to the international 10–20 system (i.e. Fp1, Fp2, F7, F3, Fz, F4, F8, T3, C3, Cz, C4, T4, T5, P3, Pz, P4, T6, O1, O2) and referenced to linked earlobes or cephalic reference. To monitor eye movements, the horizontal and vertical electrooculogram (0.3–70 Hz bandpass) was simultaneously recorded. All data were digitized in continuous recording mode (about 5 min of EEG; 128–512 Hz sampling rate, the sampling rate being fixed in each recording research unit of this multi-centric study). In all subjects, EEG recordings were performed in the late morning. In order to keep constant the level of vigilance, an operator controlled on-line the subject and the EEG traces, verbally alerting the subject any time there were signs of behavioral and/or EEG drowsiness.

Preliminary analysis of the EEG data

The recorded EEG data were segmented and analyzed off-line in consecutive 2 s epochs. The EEG epochs with ocular, muscular, and other types of artifacts were preliminarily identified by a computerized automatic procedure. EEG epochs with sporadic blinking artifacts (less than 15% of the total) were then corrected by an autoregressive method [51]. Two independent experimenters – blind to the diagnosis at the time of the EEG analysis – manually confirmed the

EEG segments accepted for further analysis. Finally, we re-referenced artifact free EEG data to common average for further analysis.

Spectral analysis of the EEG data

The digital FFT-based power spectrum analysis (Welch technique, Hanning windowing function, no phase shift) was evaluated in order to calculate the individual alpha frequency (IAF) peak, defined as the frequency associated to the strongest EEG power at the extended alpha range of 6–13 Hz [53]. Mean IAF peak was 9.3 Hz (±0.2 SE) in the Nold subjects, 9.5 Hz (±0.1 SE) in the MCI subjects, and 8.8 Hz (±0.2 SE) in the AD subjects. No statistically significant ANOVA differences were found ($p>0.05$). However, the IAF peak was used as a covariate (together with age, gender, recording unit site, and use or not of the ADNI protocol in the statistics analyses. Indeed, the IAF is a frequency of special importance, since it is associated with maximum power of resting eyes-closed EEG rhythms [52]. The above procedure minimized the possibility that small differences in the IAF peak could confound the comparisons among the Nold, MCI, and AD groups. The standard frequency bands of interest were delta (2–4 Hz), theta (4–8 Hz), alpha 1 (8–10.5 Hz), alpha 2 (10.5–13 Hz), beta 1 (13–20 Hz), beta 2 (20–30 Hz) and gamma (30–40 Hz), in continuity with a bulk of reference previous studies on the cortical sources of resting EEG rhythms in pathological aging [8, 14, 53–56]. Choice of the fixed EEG bands did not account for IAF peak. However, this should not affect the results, since more than 90% of the subjects had the IAF peaks within the alpha 1 band (8–10.5 Hz) and the IAF was used as a covariate in the statistical analysis.

Cortical source of EEG rhythms as computed by LORETA

Low resolution electromagnetic source tomography (LORETA) as provided at <http://www.unizh.>

ch/keyinst/NewLORETA/LORETA01.htm was used for the estimation of cortical sources of EEG rhythms [57–59]. LORETA is a functional imaging technique belonging to a family of linear inverse solution procedures [60] modeling 3D distributions of EEG sources [59]. With respect to the dipole modeling of cortical sources, no a priori decision of the dipole position is required by LORETA procedure. LORETA belongs to the family of linear inverse algorithms like minimum norm solution, weighted minimum norm solution or weighted resolution optimization [58, 61, 62], and has been successfully used in recent EEG studies on pathological brain aging using the same experimental set up (electrode montage, sample frequency, etc.) of the present study [3, 7, 14, 53–56].

LORETA computes 3D linear solutions (LORETA solutions) for the EEG inverse problem within a 3-shell spherical head model including scalp, skull, and brain compartments. The brain compartment is restricted to the cortical gray matter/hippocampus of a head model co-registered to the Talairach probability brain atlas and digitized at the Brain Imaging Center of the Montreal Neurological Institute [63]. This compartment includes 2394 voxels (7 mm resolution), each voxel containing an equivalent current dipole. Of note, EEG electrode positions were not co-registered to individual brain source models; unfortunately, the official LORETA package did not include software to do so and we could not obtain the digitalization of the electrode position from our clinical units. LORETA can be used from EEG data recorded by low spatial sampling of 10–20 system (19 electrodes) when cortical sources are estimated from resting state eyes-closed EEG rhythms [1, 7, 14, 17, 23, 53–56, 64–71]. Indeed, resting state eyes-closed EEG rhythms are generated by coherent synchronous neural activity of large cortical areas (i.e., the summed activity of a large number of pyramidal neuron assemblies). As a result, these rhythms are characterized by low-spatial frequency content that can be properly sampled by the 19 scalp electrodes placed according to 10–20 system [72].

LORETA solutions consisted of voxel z -current density values able to predict EEG spectral power density at scalp electrodes, being a reference-free method of EEG analysis, in that one obtains the same LORETA source distribution for EEG data referenced to any reference electrode including common average. A normalization of the data was obtained by normalizing the LORETA current density at each voxel with the power density averaged across all frequencies (0.5–45 Hz) and across all 2394 voxels of the brain volume. After the normalization, the solutions lost the original physi-

cal dimension and were represented by an arbitrary unit scale. This procedure reduced inter-subjects variability and was used in previous EEG studies [7, 14, 53–56]. The general procedure fitted the LORETA solutions in a Gaussian distribution and reduced inter-subject variability [73, 74]. Other methods of normalization using the principal component analysis are effective for estimating the subjective global factor scale of the EEG data [75]. These methods are not available in the LORETA package, so they were not used in this study.

Solutions of the EEG inverse problem are underdetermined and ill conditioned when the number of spatial samples (electrodes) is lower than that of the unknown samples (current density at each voxel). In order to properly address this problem, the cortical LORETA solutions predicting scalp EEG spectral power density were regularized to estimate distributed rather than punctual EEG source patterns [57–59]. In line with the low spatial resolution of the adopted technique, we used our MATLAB software to collapse all voxels of LORETA solutions within each of the cortical macroregions of interest (ROIs) such frontal, central, parietal, occipital, temporal, and limbic regions of the brain model. The belonging of a LORETA voxel to a Brodmann area was defined by original LORETA package. Table 3 lists the Brodmann areas (BAs) represented into each ROI.

A main advantage of the regional analysis of LORETA solutions, using an explicit source model coregistered into Talairach space, was that our modeling could disentangle rhythms of contiguous cortical areas (namely those from the occipital source were disentangled with respect to those of the contiguous parietal and temporal sources, etc).

Statistical analysis of the LORETA solutions

Statistical analysis aimed at evaluating two main working hypotheses. These hypotheses were the following: (1) LORETA solutions of resting state cortical

Table 3
Brodmann areas included in the cortical regions of interest (ROIs) of the present study. LORETA solutions were collapsed in frontal, central, parietal, occipital, temporal, and limbic ROIs

LORETA Brodmann areas into the regions of Interest (ROIs)	
Frontal	8, 9, 10, 11, 44, 45, 46, 47
Central	1, 2, 3, 4, 6
Parietal	5, 7, 30, 39, 40, 43
Temporal	20, 21, 22, 37, 38, 41, 42
Occipital	17, 18, 19
Limbic	31, 32, 33, 34, 35, 36

437 EEG rhythms show difference in amplitude among the
438 Nold, MCI, and AD subjects; (2) LORETA solutions
439 point to difference in amplitude between AD+ and
440 AD- groups as well as between MCI+ and MCI-
441 groups. The LORETA solutions showing such signif-
442 icant differences are correlated to the cognitive status
443 as revealed by MMSE score.

444 To test the first working hypothesis, the LORETA
445 solutions values were used as a dependent variable
446 for an ANOVA design using subjects' age, gender,
447 MMSE, IAF peak, and recording unit site as covari-
448 ates. The ANOVA factors (levels) were Group (Nold,
449 MCI, AD), Band (delta, theta, alpha 1, alpha 2, beta
450 1, beta 2, gamma), and ROI (frontal, central, parietal,
451 occipital, temporal, limbic). Mauchly's test evaluated
452 the sphericity assumption. Correction of the degrees of
453 freedom was made with the Greenhouse-Geisser pro-
454 cedure. Duncan test was used for post-hoc comparisons
455 ($p < 0.05$). Specifically, the working hypothesis would
456 be confirmed by a statistical ANOVA effect includ-
457 ing the factor Group ($p < 0.05$), and planned post-hoc
458 testing showing differences in line with the pattern
459 $Nold \neq MCI \neq AD$ ($p < 0.05$).

460 To test the second working hypothesis, the LORETA
461 solutions values were used as a dependent variable for
462 an ANOVA design using subjects' age, gender, MMSE,
463 IAF peak, and recording unit site as covariates. The
464 ANOVA factors (levels) were Group (MCI+, MCI-,
465 AD+, AD-), Band (delta, theta, alpha 1, alpha 2, beta
466 1, beta 2, gamma), and ROI (frontal, central, parietal,
467 occipital, temporal, limbic). Mauchly's test evaluated
468 the sphericity assumption. Correction of the degrees
469 of freedom was made with the Greenhouse-Geisser
470 procedure. Duncan test was used for post-hoc com-
471 parisons ($p < 0.05$). The working hypothesis would be
472 confirmed by a statistical ANOVA effect including the
473 factor Group ($p < 0.05$), and planned post-hoc testing
474 showing differences between AD+ and AD- groups
475 as well as between MCI+ and MCI- groups. Finally,
476 EEG sources showing these statistically significant dif-
477 ferences as a function of the white matter vascular
478 lesions were correlated to MMSE score in the con-
479 tinuum of the MCI and AD subjects as a whole group
480 (Pearson test, $p < 0.05$).

481 *Novelty of the present study*

482 This study is a part of larger scientific program on
483 EEG markers of AD, yet it is well framed and dis-
484 tinct from the previous studies of the Authors [7, 14,
485 53–56]. Specifically, this is our first study examining
486 the relationships between resting state EEG sources

487 and white matter vascular lesions in AD. To address
488 this issue, we performed an unedited analysis of white
489 matter vascular lesions by EMS-SPM software in 83
490 AD patients and 96 amnesic MCI subjects, for the com-
491 parison of EEG sources between sub-groups of these
492 subjects with a different degree of white matter vascu-
493 lar lesion. Among these subjects, no AD patient and 64
494 amnesic MCI subjects had been previously used in the
495 reference investigations evaluating white matter vascu-
496 lar lesions by Wahlund visual rating scale [1, 23]. The
497 results of the present analysis are absolutely original
498 (i.e., never published before).

499 RESULTS

500 Figure 1 shows the grand average of regional
501 normalized LORETA solutions (i.e., relative power
502 current density averaged with each ROI) relative to an
503 ANOVA interaction ($F(60,6480) = 11.91$; $p < 0.0001$)
504 among the factors Group (Nold, MCI, AD), Band
505 (delta, theta, alpha 1, alpha 2, beta 1, beta 2, gamma),
506 and ROI (frontal, central, parietal, occipital, tempo-
507 ral, limbic). Planned post-hoc testing indicated that
508 occipital alpha2 sources as well as parietal, occip-
509 ital, temporal, and limbic alpha 1 sources were
510 higher in amplitude in the Nold than MCI group
511 ($p < 0.000005$), and in the MCI than AD group
512 ($p < 0.000005$ to 0.000001); these results disclosed
513 the pattern $Nold > MCI > AD$ for the parietal, occip-
514 ital, temporal, and limbic alpha 1 and occipital alpha2
515 sources. Furthermore, frontal, temporal, and limbic
516 delta sources were lower in amplitude in the Nold and
517 MCI than in the AD groups ($p < 0.05$).

518 Figure 2 maps the grand average of the normalized
519 LORETA solutions (i.e., relative power current den-
520 sity) modeling the distributed cortical EEG sources
521 for delta, theta, alpha 1, alpha 2, beta 1, beta 2, and
522 gamma bands in the AD-, AD+, MCI-, MCI+ groups.
523 Posterior alpha sources were generally higher in ampli-
524 tude in the AD+ or MCI+ than AD- or MCI- group,
525 whereas the opposite is true for the posterior delta
526 sources.

527 Figure 3 plots the grand average of regional normal-
528 ized LORETA solutions (i.e., relative power current
529 density averaged with each ROI) relative to an ANOVA
530 interaction ($F(90,5250) = 3.50$; $p < 0.00001$) among
531 the factors Group (AD-, AD+, MCI-, MCI+), Band
532 (delta, theta, alpha 1, alpha 2, beta 1, beta 2, gamma),
533 and ROI (frontal, central, parietal, occipital, tempo-
534 ral, limbic). Planned post-hoc testing indicated that
535 occipital, temporal, and limbic alpha 1 sources were




Fig. 1. Statistical ANOVA interaction ($F(60,6480) = 11.91; p < 0.0001$) among the factors Group (Nold, MCI, AD), Band (delta, theta, alpha 1, alpha 2, beta 1, beta 2, gamma), and ROI (frontal, central, parietal, occipital, temporal, limbic).

536 higher in amplitude in the MCI+ than MCI- group
 537 ($p < 0.01$ to 0.000001). Furthermore, occipital
 538 delta sources were higher in amplitude in the AD- than
 539 AD+ group ($p < 0.01$). Finally, central, parietal, occipital,
 540 temporal, and limbic alpha sources were higher in amplitude in the AD+ than AD- group ($p < 0.05$ to
 541 0.000001).
 542

543 The mentioned delta and alpha sources showing
 544 statistically significant differences ($p < 0.05$) as a function
 545 of the white matter vascular lesions (i.e., MCI+
 546 or AD+ versus MCI- or AD-) were correlated
 547 to MMSE score in the continuum of the MCI and
 548 AD subjects as a whole group. There was a positive
 549 correlation between MMSE score and any of the
 550 mentioned alpha sources at central (alpha 1, $r = 0.18$,
 551 $p = 0.02$; alpha 2, $r = 0.20$, $p = 0.008$), parietal (alpha
 552 1, $r = 0.28$, $p = 0.0001$; alpha 2, $r = 0.32$, $p = 0.0001$),
 553 occipital (alpha 1, $r = 0.25$, $p = 0.001$; alpha 2, $r = 0.27$,
 554 $p = 0.0001$), temporal (alpha 1, $r = 0.31$, $p = 0.0001$;

555 alpha 2, $r = 0.26$, $p = 0.001$), and limbic (alpha 1,
 556 $r = 0.30$, $p = 0.0001$; alpha 2, $r = 0.30$, $p = 0.0001$)
 557 macroregions. The higher the MMSE score, the higher
 558 the amplitude of alpha sources. Furthermore, there was
 559 a negative correlation between MMSE score and occipital
 560 delta sources ($r = -0.31$, $p = 0.0001$). The lower
 561 the MMSE score, the higher the amplitude of occipital
 562 delta sources.

563 Control analyses

564 We performed some control analyses to ascertain if
 565 the results of the main statistical analysis were affected
 566 by relevant confounding variables.

567 In a first control analysis, we tested whether the
 568 statistical results were influenced by the presence of
 569 ADNI and non-ADNI subjects in the MCI and AD
 570 groups. We divided the MCI and AD group in ADNI




Fig. 2. Grand average of LORETA solutions (i.e., normalized relative current density at the cortical voxels) modeling the distributed EEG sources for delta, theta, alpha 1, alpha 2, beta 1, beta 2, and gamma bands in Nold, MCI - (normalized white-matter vascular lesions < 4960), MCI+(normalized white-matter vascular lesions ≥ 4960), AD - (normalized white-matter vascular lesions < 3430), and AD+(normalized white-matter vascular lesions ≥ 3430) groups. The left side of the maps (top view) corresponds to the left hemisphere. Legend: LORETA, low resolution brain electromagnetic tomography. Color scale: all power density estimates were scaled based on the averaged maximum value (i.e., alpha 1 power value of occipital region in Nold).

571 (18 MCI and 50 AD) and non-ADNI (78 MCI and
 572 33 AD). Statistical analysis of the LORETA source
 573 solutions showed no statistically significant difference
 574 ($F(1.91) = 0.01$; $p < 0.9235$) between MCI ADNI and
 575 MCI non-ADNI sub-groups. The same was true in
 576 AD patients, namely no statistically significant dif-
 577 ference ($F(1.78) = 0.49$; $p < 0.4839$) between the AD
 578 ADNI and AD non-ADNI sub-groups.

579 In a second control analysis, we compared the Nold,
 580 MCI, and AD groups matched as number (40 AD,
 581 40 MCI, and 40 Nold subjects), mean age (AD = 69.5
 582 years; MCI = 69.8 years; Nold = 72.1 years), and mean

583 IAF (AD = 8.6, MCI = 9.3, and Nold = 9.3 hertz). This
 584 allowed a good control of the inter-groups variabil-
 585 ity. The ANOVA design and covariates were those of
 586 the main ANOVA design. The ANOVA factors were
 587 Group (Nold, MCI, AD), Band (delta, theta, alpha 1,
 588 alpha 2, beta 1, beta 2, gamma), and ROI (frontal, cen-
 589 tral, parietal, occipital, temporal, limbic). The results
 590 showed a statistically significant interaction among all
 591 factors ($F(60,3510) = 14.17$; $p < 0.0001$). As expected,
 592 ANOVA showed the well known abnormalities of delta
 593 and alpha sources, in detail the results disclosed the pat-
 594 tern Nold > MCI > AD for the parietal, occipital, and




Fig. 3. Statistical ANOVA interaction ($F(90,5250)=3.50$; $p<0.00001$) among the factors Group (AD-, AD+, MCI-, MCI+), Band (delta, theta, alpha 1, alpha 2, beta 1, beta 2, gamma), and ROI (frontal, central, parietal, occipital, temporal, limbic).

limbic alpha and temporal alpha1 sources. Furthermore, frontal, occipital, and temporal delta sources were lower in amplitude in the Nold and MCI than in the AD groups ($p<0.05$). These results globally confirmed those of the main analysis.

In a third control analysis, we compared white matter vascular lesions between MCI+ versus MCI- groups as well as between AD+ versus AD- groups. As expected, ANOVA showed that there were significantly higher values of the white matter vascular lesions in the MCI+ than MCI- ($p<0.00001$) as well as in the AD+ than AD- subjects ($p<0.00001$).

A fourth control analysis accounted for the variability of the MMSE score across the groups, although the MMSE score was used as a covariate in the main ANOVA design. We selected sub-groups of AD-, AD+, MCI-, and MCI+ subjects to minimize the difference of MMSE score between the AD- and AD+ groups as well as between the MCI- and MCI+ groups (Table 4). The ANOVA design and covariates were

those of the main ANOVA design. The ANOVA factors were Group (AD-, AD+, MCI-, MCI+; independent variable), Band (delta, theta, alpha 1, alpha 2, beta 1, beta 2, gamma), and ROI (central, frontal, parietal, occipital, temporal, limbic). The results showed a statistically significant interaction among all factors ($F(90,2700)=2.81$; $p<0.00001$). Planned post-hoc testing indicated that central and temporal alpha 1 sources were higher in amplitude in the MCI+ than MCI- group ($p<0.05$). Furthermore, occipital delta sources were lower in amplitude in the AD+ than AD- group ($p<0.05$). Finally, central, parietal, occipital, and temporal alpha 1 sources were higher in amplitude in the AD+ than AD- group ($p<0.01$). These results globally confirmed those of the main ANOVA design.

DISCUSSION

In the present study, we tested the novel hypothesis that in AD subjects, resting state closed-eye EEG

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

Table 4

Demographic and clinical data of the subjects' sub-groups created to minimize the difference of MMSE between AD- and AD+ as well as between MCI- and MCI+

	Subjects (n)	Gender (M/F)	Age (years)	MMSE	IAF (Hz)	White matter vascular lesion (voxels)
MCI+	28	12/21	68.3 ± (1.5 SE)	26.3 ± (0.3 SE)	9.6 ± (0.2 SE)	7800 ± (713 SE)
MCI-	28	13/20	69.0 ± (1.1 SE)	26.2 ± (0.3 SE)	9.5 ± (0.2 SE)	2973 ± (227 SE)
AD+	19	8/11	72.1 ± (1.8 SE)	19.5 ± (0.8 SE)	8.8 ± (0.3 SE)	9795 ± (2403 SE)
AD-	19	7/12	70.1 ± (2.7 SE)	19.6 ± (0.8 SE)	8.4 ± (0.4 SE)	2231 ± (200 SE)

rhythms are not deteriorated due to the amount of white-matter vascular lesion, thus extending previous evidence in amnesic MCI subjects [1, 23]. To address this hypothesis, we estimated white matter vascular lesion with friendly and automated software (i.e., EMS tool of SPM) towards possible clinical applications. Such procedure was based on the use of PD, T1-, and T2-weighted MRIs recorded in amnesic MCI and AD subjects. Of note, we collected about 42% of the MRIs following the standards of the ADNI project (<http://www.adni-info.org/>), which aims at standardizing neuroimaging exams of aged people in multicenter AD studies on new markers and drugs. In this vein, we estimated cortical sources of resting state EEG rhythms by LORETA software, which can be freely downloaded by Internet (<http://www.unizh.ch/keyinst/NewLORETA/LORETA01.htm>), and has been successfully used by our Consortium in several field investigations [7, 14, 53–56].

In the present study, results of the control statistical analysis confirmed that the amnesic MCI subjects showed a decrease in amplitude of low-frequency alpha sources (8–10.5 Hz) compared to the Nold subjects. The AD subjects were characterized by an amplitude increase of delta sources (2–4 Hz), along with a strong amplitude reduction of low-frequency alpha sources. These findings are globally in line with previous evidence showing a pathological enhancement of the delta rhythms in AD subjects [7, 8, 76, 77], and a magnitude decrease of default alpha rhythms in MCI and/or AD subjects [2, 3, 7, 8, 15, 21, 22, 78]. Therefore, these control findings validated the present procedures for subjects' selection and EEG data analysis, thus corroborating the novel results on the relationships between resting state EEG sources and white matter vascular lesions in AD subjects.

Results of the main statistical analysis indicated that amplitude of posterior low-frequency alpha sources was higher in the amnesic MCI+ than MCI- group. As a novel finding, amplitude of occipital delta sources was lower in the AD+ than AD- group, whereas the

opposite was true for central and posterior low- and high-frequency alpha sources. These results suggest that in AD subjects, central and posterior resting state delta and alpha rhythms are not deteriorated with the increase of white-matter vascular lesion, thus extending previous evidence on alpha sources in amnesic MCI subjects [1, 23].

Why were resting state EEG rhythms not deteriorated by the increase of white matter vascular lesions in amnesic MCI and AD subjects? To answer to this question, a brief overview on “normal” delta and alpha rhythms is helpful. In the condition of slow-wave sleep, corticofugal slow oscillations (<1 Hz) are effective in grouping thalamic-generated delta rhythms (1–4 Hz) and spindling activity (7–14 Hz) rhythms [79]. In the condition of brain arousal, spindles as well as high and low-frequency components of the delta rhythms are blocked by the inhibition of oscillators within, respectively, reticulo-thalamic (7–14 Hz), thalamo-cortical (1–4 Hz), and intracortical (<1 Hz) neuronal circuits. These rhythms are replaced by fast (beta and gamma) cortical oscillations, which are mainly induced by forebrain (nucleus basalis) cholinergic inputs to hippocampus and cortex as well as by thalamocortical projections [79, 80]. In the condition of awake rest, low-frequency (8–10.5 Hz) alpha would be mainly related to subject's global attentional readiness [72, 81–84] and would mainly reflect time-varying inputs of cortico-cortical and thalamo-cortical pathways [85]. Noteworthy, there is consensus that alpha rhythms represent the dominant resting oscillations of the adult, awake human brain [72, 81–84], and have been linked to intelligent quotient, memory, and cognition [52]. Keeping in mind this physiological premise, loss of synapses and neurons along the well known tracks of AD neurodegeneration [86, 87] may deteriorate the synchronization of cortical pyramidal neurons generating default alpha rhythms, and may disinhibit pathological delta rhythms in the condition of resting state. In this framework, diffuse white matter vascular lesions may not specifically

715 impair the neural circuits responsible for the transfer
716 of signals into brain pathways that generate resting
717 state alpha rhythms and inhibit pathological delta
718 rhythms.

719 The present results support the notion that cere-
720 brovascular and AD lesions do not represent additive
721 or synergistic factors in the determination of the rest-
722 ing state EEG abnormalities during the evolution of the
723 disease, although these lesions contribute to the
724 development of cognitive impairment in AD patients
725 [24, 26, 88]. In AD, cognitive and clinical conditions
726 are affected by the severity of both neurodegenerative
727 and cerebrovascular lesions in hippocampal,
728 anterior cingulate gyrus, and parieto-temporal regions
729 [89, 90–94]. Furthermore, these conditions depend on
730 amyloid angiopathy of small vessels and on their struc-
731 ture/function [27–29]. Current evidence suggests that
732 there is decreased vascular density in aging and AD,
733 with a cerebrovascular dysfunction that precedes and
734 accompanies cognitive dysfunction and neurodegener-
735 ation [95]. A decline in cerebrovascular angiogenesis
736 typically inhibits recovery from hypoxia-induced cap-
737 illary loss and cerebral blood flow may be inhibited by
738 tortuous arterioles and deposition of excessive collagen
739 in veins and venules [96]. In this framework, hypoper-
740 fusion may occur early in AD, inducing white matter
741 lesions and correlating with dementia [95–99]. How-
742 ever, resting state EEG abnormalities would be mainly
743 affected by the AD neurodegenerative impairment of
744 brain circuits, which may be not specifically targeted
745 by diffuse white matter vascular lesions. Therefore, it
746 can be speculated that resting state EEG rhythms might
747 be more sensitive to neurodegenerative processes than
748 cerebrovascular lesions in AD.

749 In conclusion, we tested whether cortical synchron-
750 ization mechanisms at the basis of resting state EEG
751 rhythms are abnormal in AD subjects, as a function
752 of vascular lesion of white matter. The present results
753 showed that in both amnesic MCI and AD subjects,
754 posterior delta and alpha sources did not deteriorate
755 with the increase of white matter vascular lesion,
756 although white matter is known to be impaired along
757 AD neurodegenerative process. These results need to
758 be validated with a follow-up study evaluating resting
759 state EEG rhythms and white matter vascular lesion. In
760 principle, the present results suggest that abnormalities
761 of resting state EEG rhythms might be related to AD
762 neurodegeneration specifically impinging on the brain
763 circuits generating these rhythms and cognitive status
764 rather than to white matter vascular lesion globally
765 affecting the whole brain.

ACKNOWLEDGMENTS

766 We thank Dr. Paul Suetens of Medical Image Com-
767 puting Group at KU Leuven, for providing software
768 EMS used for MRI data analysis. We also thank
769 Prof./Drs. Carla Buttinelli, Brunello Lecce, Anna-
770 maria Papantonio, Paolo Tisei, Antonella De Carolis,
771 Silvia Guidoni, Teresa Falco, Daniela Buonanno,
772 Manuela De Stefano, Federica Scrascia, Livia Quin-
773 tiliani, Simone Migliore, Daniela Cologno, Loreto
774 Gesualdo, Elena Ranieri, Ivan Cincione, Antonello
775 Bellomo, Annamaria Petito, Mario Altamura, Pietro
776 Fiore, Andrea Santamato, Tommaso Cassano, Dario
777 Colella, Giuseppe Cibelli, and Giancarlo Rossi-Fedele
778 for their excellent clinical, biometrics, tecnica, and
779 data analysis work. This research was developed
780 thank to the financial support of Tosinvest Sanita'
781 (Cassino, Pisana) and Italian Ministry of Health
782 (Strategic research project entitled “Diagnosis of incip-
783 ient Alzheimer disease”) for the collection but not for
784 the analysis of the data reported in this manuscript.
785 The research leading to the present results has also
786 received funding from the European Community’s
787 Seventh Framework Programme (FP7/2007–2013) for
788 the Innovative Medicine Initiative under Grant Agree-
789 ment no 115009 (Prediction of cognitive properties
790 of new drug candidates for neurodegenerative dis-
791 eases in early clinical development, Pharmacog). It
792 was conducted as part of the analysis of “historical”
793 (archive) EEG and MRI data in control, amnesic MCI,
794 and AD subjects performed by two units of the Phar-
795 maCog Consortium, namely the University of Foggia
796 (Prof./Dr. Claudio Babiloni, Loreto Gesualdo, Elena
797 Ranieri, Ivan Cincione, Antonello Bellomo, Anna-
798 maria Petito, Mario Altamura, Pietro Fiore, Andrea
799 Santamato, Tommaso Cassano, Dario Colella, and
800 Gaetano Serviddio) and IRCCS Fatebenefratelli of
801 Brescia (Dr. Giovanni B. Frisoni, Marina Boccardi,
802 and Alberto Redolfi). PharmaCog funding was used
803 to support the analysis but not the collection of the
804 data reported in this manuscript. After a gentleman
805 agreement among all participants to this research,
806 only Prof./Dr. Claudio Babiloni, Fabrizio Vecchio,
807 Giovanni B. Frisoni, Marina Boccardi, and Alberto
808 Redolfi represented the PharmaCog Consortium in the
809 Author list. We thank Prof./Drs. Elaine Irving, Gian-
810 luigi Forloni, Francesco Mattia Noe’, Tilman Hensch,
811 Oscar Dalla Pasqua, David Bartrés-Faz, David Wille,
812 Giuseppe Bertini, and Paolo Fabene for a fruitful sci-
813 entific discussion of the results in the framework of the
814 PharmaCog Consortium. For further information on
815

the PharmaCog project please refer to www.alzheimer-europe.org.

Authors' disclosures available online (<http://www.j-alz.com/disclosures/view.php?id=847>).

REFERENCES

- [1] Babiloni C, Frisoni GB, Pievani M, Toscano L, Del Percio C, Geroldi C, Eusebi F, Miniussi C, Rossini PM (2008) White-matter vascular lesions correlate with alpha EEG sources in mild cognitive impairment. *Neuropsychologia* **46**, 1707-1720.
- [2] Dierks T, Ihl R, Frolich L, Maurer K (1993) Dementia of the Alzheimer type: effects on the spontaneous EEG described by dipole sources. *Psychiatry Res* **50**, 51-162.
- [3] Dierks T, Jelic V, Pascual-Marqui RD, Wahlund LO, Julin P, Linden DEJ, Maurer K, Winblad B, Nordberg A (2000) Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzheimer's disease. *Clinical Neurophysiology* **111**, 1817-1824.
- [4] Huang C, Wahlund LO, Dierks T, Julin P, Winblad B, Jelic V (2000) Discrimination of Alzheimer's disease and mild cognitive impairment by equivalent EEG sources: a cross-sectional and longitudinal study. *Clin Neurophysiol* **11**, 1961-1967.
- [5] Ponomareva NV, Selesneva ND, Jarikov GA (2003) EEG alterations in subjects at high familial risk for Alzheimer's disease. *Neuropsychobiology* **48**, 152-159.
- [6] Jeong J (2004) EEG dynamics in patients with Alzheimer's disease. *Clin Neurophysiol* **115**, 1490-1505.
- [7] Babiloni C, Binetti G, Cassetta E, Cerboneschi D, Dal Forno G, Del Percio C, Ferreri F, Ferri R, Lanuzza B, Miniussi C, Moretti DV, Nobili F, Pascual-Marqui RD, Rodriguez G, Romani GL, Salinari S, Tecchio F, Vitali P, Zanetti O, Zappasodi F, Rossini PM (2004) Mapping Distributed Sources of Cortical Rhythms in Mild Alzheimers Disease. A Multi-Centric EEG Study. *NeuroImage* **22**, 57-67.
- [8] Koenig T, Prichep L, Dierks T, Hubl D, Wahlund LO, John ER, Jelic V (2005) Decreased EEG synchronization in Alzheimer's disease and mild cognitive impairment. *Neurobiol Aging* **26**, 165-171.
- [9] Zappoli R, Versari A, Paganini M, Arnetoli G, Muscas GC, Gangemi PF, Arneodo MG, Poggiolini D, Zappoli F, Battaglia A (1995) Brain electrical activity (quantitative EEG and bit-mapping neurocognitive CNV components), psychometrics and clinical findings in presenile subjects with initial mild cognitive decline or probable Alzheimer-type dementia. *Ital J Neurol Sci* **16**, 341-376.
- [10] Jelic V, Julin P, Shigeta M, Nordberg A, Lannfelt L, Winblad B, Wahlund LO (1997) Apolipoprotein E epsilon4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence. *J Neurol Neurosurg Psychiatry* **63**, 59-65.
- [11] Grunwald M, Busse F, Hensel A, Kruggel F, Riedel-Heller S, Wolf H, Arendt T, Gertz HJ (2001) Correlation between cortical theta activity and hippocampal volumes in health, mild cognitive impairment, and mild dementia. *J Clin Neurophysiol* **18**, 178-184.
- [12] Jelic V, Johansson SE, Almkvist O, Shigeta M, Julin P, Nordberg A, Winblad B, Wahlund LO (2000) Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease. *Neurobiol Aging* **21**, 533-540.
- [13] Grunwald M, Busse F, Hensel A, Riedel-Heller S, Kruggel F, Arendt T, Wolf H, Gertz HJ (2002) Theta-power differences in patients with mild cognitive impairment under rest condition and during haptic tasks. *Alzheimer Dis Assoc Disord*. Jan-Mar **16**, 40-48.
- [14] Babiloni C, Binetti G, Cassetta E, Dal Forno G, Del Percio C, Ferreri F, Ferri R, Frisoni G, Hirata K, Lanuzza B, Miniussi C, Moretti DV, Nobili F, Rodriguez G, Romani GL, Salinari S, Rossini PM (2006) Sources of cortical rhythms change as a function of cognitive impairment in pathological aging: A multi-centric study. *Clin Neurophysiol* **117**, 252-268.
- [15] Rossini PM, Rossi S, Babiloni C, Polich J (2007) Clinical neurophysiology of aging brain: from normal aging to neurodegeneration. *Prog Neurobiol* **83**, 375-400.
- [16] Elmstahl S, Rosen I (1997) Postural hypotension and EEG variables predict cognitive decline: results from a 5-year follow-up of healthy elderly women. *Dement Geriatr Cogn Disord* **8**, 180-187.
- [17] Babiloni C, Frisoni GB, Pievani M, Vecchio F, Lizio R, Buttiglione M, Geroldi C, Fracassi C, Eusebi F, Ferri R, Rossini PM (1) (2009a) Hippocampal volume and cortical sources of EEG alpha rhythms in mild cognitive impairment and Alzheimer disease. *Neuroimage* **44**, 123-135.
- [18] Babiloni C, Frisoni GB, Vecchio F, Pievani M, Geroldi C, De Carli C, Ferri R, Vernieri F, Lizio R, Rossini PM (2010) Global functional coupling of resting EEG rhythms is related to white-matter lesions along the cholinergic tracts in subjects with amnesic mild cognitive impairment. *J Alzheimers Dis* **19**, 859-871.
- [19] Sloan EP, Fenton GW, Kennedy NSJ, MacLennan JM (1995) Electroencephalography and single photon emission computed tomography in dementia: A comparative study. *Psychol Med* **25**, 631-638.
- [20] Rodriguez G, Nobili F, Rocca G, DeCarli F, Gianelli MV, Rosadini G (1998) Quantitative electroencephalography and regional cerebral blood flow: Discriminant analysis between Alzheimer's patients and healthy controls. *Dement Geriatr Cogn Disord* **9**, 238-274.
- [21] Rodriguez G, Copello F, Vitali P, Perego G, Nobili F (1999) EEG spectral profile to stage Alzheimer's disease. *Clin Neurophysiol* **110**, 1831-1837.
- [22] Rodriguez G, Nobili F, Copello F, Vitali P, Gianelli MV, Taddei G, Catsafados E, Mariani G (1999) 99mTc-HMPAO regional Cerebral Blood Flow and quantitative Electroencephalography in Alzheimer's disease: a correlative study. *J Nucl Med* **40**, 522-529.
- [23] Babiloni C, Frisoni GB, Pievani M, Vecchio F, Infarinato F, Geroldi C, Salinari S, Ferri R, Fracassi C, Eusebi F, Rossini PM (2008) White matter vascular lesions are related to parietal-to-frontal coupling of EEG rhythms in mild cognitive impairment. *Hum Brain Mapp* **29**, 1355-1367.
- [24] Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of Alzheimer disease. *The Nun Study, JAMA* **277**, 813-817.
- [25] Nagy Z, Esiri MM, Jobst KA, Morris JH, King EM-F, McDonald B, Joachim C, Litchfield S, Barnettson L, Smith AD (1997) The effects of additional pathology on the cognitive deficit in Alzheimer disease. *J Neuropathol Exp Neurol* **56**, 165-170.
- [26] Zekry D, Duyckaerts C, Moulins R, Belmin J, Geoffre C, Herrmann F, Hauw JJ (2002) Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. *Acta Neuropathol* **103**, 481-487.

- 940 [27] Zekry D, Duyckaerts C, Belmin J, Geoffre C, Herrmann F, 1005
 941 Moulias R, Hauw JJ (Aging) (2003) The vascular lesions 1006
 942 in vascular and mixed dementia: The weight of functional 1007
 943 neuroanatomy. *Neurobiol Aging* **24**, 213-219. 1008
- 944 [28] Altamura C, Squitti R, Pasqualetti P, Tibuzzi F, Silvestrini M, 1009
 945 Ventriglia MC, Cassetta E, Rossini PM, Vernieri F (2007) 1010
 946 What is the relationship among atherosclerosis markers, 1011
 947 apolipoprotein E polymorphism and dementia? *Eur J Neurol* 1012
 948 **14**, 679-682. 1013
- 949 [29] Silvestrini M, Pasqualetti P, Baruffaldi R, Bartolini M, Hand- 1014
 950 douk Y, Matteis M, Moffa F, Provinciali L, Vernieri F. (2006) 1015
 951 Cerebrovascular reactivity and cognitive decline in patients 1016
 952 with Alzheimer disease, *Stroke* **37**, 1010-1015 1017
- 953 [30] Albert M, Smith LA, Scherr PA, Taylor JO, Evans DA, 1018
 954 Funkenstein HH (1991) Use of brief cognitive tests to identify 1019
 955 individuals in the community with clinically diagnosed 1020
 956 Alzheimer's disease. *Int J Neurosci* **57**, 167-178. 1021
- 957 [31] Devanand DP, Folz M, Goryn M, Moeller JR, Stem J (1997) 1022
 958 Questionable dementia: clinical course and predictors of outcome. 1023
 959 *J Am Geriatr Soc* **45**, 321-328. 1024
- 960 [32] Flicker CS, Ferris H, Reisberg B (1991) Mild cognitive 1025
 961 impairment in the elderly: predictors of dementia. *Neurology* 1026
 962 **41**, 1006-1009. 1027
- 963 [33] Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid SN, 1028
 964 Thibodeau SN, Kokmen E, Waring SC, Kurland LT (1995) 1029
 965 Apolipoprotein E status as a predictor of the development of 1030
 966 Alzheimer's disease in memory-impaired individuals. *JAMA* 1031
 967 **273**, 1274-1278. 1032
- 968 [34] Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, 1033
 969 Tangalos EG (1997) Aging, memory, and mild cognitive 1034
 970 impairment. *Int Psychogeriatr* **9 Suppl 1**, 65-69. 1035
- 971 [35] Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins 1036
 972 PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current 1037
 973 concepts in mild cognitive impairment. *Arch Neurol* **58**, 1985- 1038
 974 1992. 1039
- 975 [36] Petersen RC (2004) Mild cognitive impairment as a diagnostic 1040
 976 entity. *J Intern Med* **256**, 183-194. 1041
- 977 [37] Rubin EH, Morris JC, Grant EA, Vendegna T (1989) Very 1042
 978 mild senile dementia of the Alzheimer type. I. Clinical assessment. 1043
 979 *Arch Neurol* **46**, 379-382. 1044
- 980 [38] Zaudig M (1992) A new systematic method of measurement 1045
 981 and diagnosis of "mild cognitive impairment" and dementia 1046
 982 according to ICD-10 and DSM-III-R criteria. *Int Psychogeriatr* 1047
 983 **4 Suppl 2**, 203-219. 1048
- 984 [39] Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili F, 1049
 985 Scheltens P, Vellas B, Touchon J (2006) MCI Working Group 1050
 986 of the European Consortium on Alzheimer's Disease Mild 1051
 987 cognitive impairment (MCI) in medical practice: a critical 1052
 988 review of the concept and new diagnostic procedure. Report 1053
 989 of the MCI Working Group of the European Consortium on 1054
 990 Alzheimer's Disease. *J Neurol Neurosurg Psychiatry* **77**, 714- 1055
 991 718. 1056
- 992 [40] McKhann G, Drachman D, Folstein M, Katzman R, 1057
 993 Price D, Stadlan (1984) Clinical diagnosis of Alzheimer's 1058
 994 disease: report of the NINCDS-ADRDA Work Group under 1059
 995 the auspices of Department of Health and Human Services 1060
 996 Task Force on Alzheimer's disease. *Neurology* **34**, 939- 1061
 997 944. 1062
- 998 [41] Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey 1063
 999 M, Leirer VO (1982-83) Development and validation of a 1064
 1000 geriatric depression screening scale: a preliminary report. *J 1065
 1001 Psychiat Res* **17**, 37-49. 1066
- 1002 [42] Folstein MF, Folstein SE, McHugh PR (1975) 'Mini Mental 1067
 1003 State': a practical method for grading the cognitive state of 1068
 1004 patients for clinician. *J Psychiat Res* **12**, 189-198. 1069
- [43] Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL 1005
 (1982) A new clinical scale for the staging of dementia. *Br J 1006
 Psychiatry* **140**, 566-572. 1007
- [44] Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A (1980) 1008
 Pathological verification of ischemic score in differentiation 1009
 of dementias. *Ann Neurol* **7**, 486-488. 1010
- [45] Lawton MP, Brodie EM (1969) Assessment of older people: 1011
 self maintaining and instrumental activity of daily living. *J 1012
 Gerontol* **9**, 179-186. 1013
- [46] Knopman DS, Boeve BF, Parisi JE, Dickson DW, Smith GE, 1014
 Ivnik RJ, Josephs KA, Petersen RC (2005) Antemortem diagnosis 1015
 of frontotemporal lobar degeneration. *Ann Neurol* **57**, 1016
 480-488. 1017
- [47] Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Mas- 1018
 deu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, 1019
 Hofman A, et al (1993) Vascular dementia: diagnostic criteria 1020
 for research studies. Report of the NINDS-AIREN International 1021
 Workshop. *Neurology* **43**, 250-260. 1022
- [48] McKeith IG, Perry EK, Perry RH (1999) Report of the second 1023
 dementia with Lewy body international workshop: diagnosis 1024
 and treatment. Consortium on Dementia with Lewy Bodies. 1025
Neurology **53**, 902-905. 1026
- [49] Van Leemput K, Maes F, Vandermeulen D, Colchester A, 1027
 Suetens P (2001) Automated segmentation of multiple sclerosis 1028
 lesions by model outlier detection. *IEEE Trans Med 1029
 Imaging* **20**, 677-688, 1030
- [50] Dempster AP, Laird NM, Rubin DB (1977) "Maximum likelihood 1031
 from incomplete data via the EM algorithm." *J Roy 1032
 Statist Soc* **39**, 1-38. 1033
- [51] Moretti DV, Babiloni F, Carducci F, Cincotti F, Remondini 1034
 E, Rossini PM, Salinari S, Babiloni C (2003) Computerized 1035
 processing of EEG-EOG-EMG artifacts for multicentric studies 1036
 in EEG oscillations and event-related potentials. *Int J 1037
 Psychophysiol* **47**, 199-216. 1038
- [52] Klimesch W (1999) EEG alpha and theta oscillations reflect 1039
 cognitive and memory performance: a review and analysis. 1040
Brain Res Rev **29**, 169-195. 1041
- [53] Babiloni C, Binetti G, Cassarino A, Dal Forno G, Del Percio 1042
 C, Ferreri F, Ferri R, Frisoni G, Galderisi S, Hirata K, Lanuzza 1043
 B, Miniussi C, Mucci A, Nobili F, Rodriguez G, Romani GL, 1044
 Rossini PM (2006) Sources of cortical rhythms in adults during 1045
 physiological aging: a multi-centric EEG study. *Human 1046
 Brain Mapp* **27**, 162-172. 1047
- [54] Babiloni C, Benussi L, Binetti G, Bosco P, Busonero G, 1048
 Cesaretti S, Dal Forno G, Del Percio C, Ferri R, Frisoni G, 1049
 Ghidoni R, Rodriguez G, Squitti R, Rossini PM (2006) Genotype 1050
 (cystatin C) and EEG phenotype in Alzheimer disease and 1051
 mild cognitive impairment: a multicentric study. *Neuroimage* 1052
29, 948-964. 1053
- [55] Babiloni C, Benussi L, Binetti G, Cassetta E, Dal Forno G, Del 1054
 Percio C, Ferreri F, Ferri R, Frisoni G, Ghidoni R, Miniussi C, 1055
 Rodriguez G, Romani GL, Squitti R, Ventriglia MC, Rossini 1056
 PM (2006) Apolipoprotein E and alpha brain rhythms in mild 1057
 cognitive impairment: A multicentric EEG study. *Ann Neurol* 1058
59, 323-334. 1059
- [56] Babiloni C, Frisoni G, Steriade M, Bresciani L, Binetti G, 1060
 Del Percio C, Geroldi C, Miniussi C, Nobili F, Rodriguez G, 1061
 Zappasodi F, Carfagna T, Rossini PM (2006) Frontal 1062
 White Matter Volume and Delta EEG Sources Negatively 1063
 Correlate In Awake Subjects With Mild Cognitive Impairment 1064
 and Alzheimer's Disease. *Clin Neurophysiol* **117**, 1113- 1065
 1129. 1066
- [57] Pascual-Marqui RD, Michel CM (1994) LORETA (low resolution 1067
 brain electromagnetic tomography): new authentic 3D 1068
 functional images of the brain. *ISBET Newsletter ISSN* **5**, 4-8. 1069

- 1070 [58] Pascual-Marqui RD, Lehmann D, Koenig T, Kochi
1071 K, Merlo MC, Hell D, Koukkou M (1999) Low resolu-
1072 tion brain electromagnetic tomography (LORETA) functional
1073 imaging in acute, neuroleptic-naive, first-episode. productive
1074 schizophrenia. *Psychiatry Res* **90**, 169-179.
- 1075 [59] Pascual-Marqui RD, Esslen M, Kochi K, Lehmann D (2002)
1076 Functional imaging with low resolution brain electromag-
1077 netic tomography (LORETA): a review. *Meth Find Exp Clin*
1078 *Pharmacol* **24**, 91-95.
- 1079 [60] Valdès P, Picton TW, Trujillo N, Bosch J, Aubert E, Riera J
1080 (1998) Constraining EEG-MEG source imaging with statisti-
1081 cal neuroanatomy. *Neuroimage* **4**, 635.
- 1082 [61] Phillips C, Rugg MD, Friston KJ (2002) Systemic regulariza-
1083 tion of linear inverse solutions of the EEG source localization
1084 problem. *Neuroimage* **17** 287-301.
- 1085 [62] Yao D, He B (2001) A self-coherence enhancement algorithm
1086 and its application to enhancing three-dimensional source
1087 estimation from EEGs. *Ann Biomed Eng* (2001) **29**, 1019-
1088 1027.
- 1089 [63] Talairach J, Tournoux P (1988). Co-Planar Stereotaxic Atlas
1090 of the Human Brain, *Stuttgart* Thieme.
- 1091 [64] Anderer P, Saletu B, Semlitsch HV, Pascual-Marqui RD
1092 (2003) Non-invasive localization of P300 sources in normal
1093 aging and age-associated memory impairment. *Neurobiol*
1094 *Aging* **24**, 463-479.
- 1095 [65] Anderer P, Saletu B, Saletu-Zyhlarz G, Gruber D, Metka M,
1096 Huber J, Pascual-Marqui RD (2004) Brain regions activated
1097 during an auditory discrimination task in insomniac post-
1098 menopausal patients before and after hormone replacement
1099 therapy: low-resolution brain electromagnetic tomography
1100 applied to event-related potentials. *Neuropsychobiology* **49**,
1101 134-153.
- 1102 [66] Babiloni C, Bosco P, Ghidoni R, Del Percio C, Squitti R,
1103 Binetti G, Benussi L, Ferri R, Frisoni G, Lanuzza B, Cas-
1104 ssetta E, Anello G, Gurzi M, Bartesaghi S, Lizio R, Tombini
1105 M, Rossini PM (2007) Homocysteine and electroencephalo-
1106 graphic rhythms in Alzheimer disease: a multicentric study.
1107 *Neuroscience* **145**, 942-954.
- 1108 [67] Babiloni C, Cassetta E, Binetti G, Tombini M, Del Percio
1109 C, Ferreri F, Ferri R, Frisoni G, Lanuzza B, Nobili F, Parisi
1110 L, Rodriguez G, Frigerio L, Gurzi M, Prestia A, Vernieri F,
1111 Eusebi F, Rossini PM (2007) Resting EEG sources corre-
1112 late with attentional span in mild cognitive impairment and
1113 Alzheimer's disease. *Eur J Neurosci* **25**, 3742-3757.
- 1114 [68] Babiloni C, Pievani M, Vecchio F, Geroldi C, Eusebi F, Fra-
1115 cassi C, Fletcher E, De Carli C, Boccardi M, Rossini PM,
1116 Frisoni GB (2009) White-matter lesions along the cholin-
1117 ergic tracts are related to cortical sources of EEG rhythms in
1118 amnesic mild cognitive impairment. *Hum Brain Mapp* **30**,
1119 1431-1443.
- 1120 [69] Laufer I, Pratt H (2003) Evoked potentials to auditory move-
1121 ment sensation in duplex perception. *Clin Neurophysiol* **114**,
1122 1316-1331.
- 1123 [70] Laufer I, Pratt H. (2003b) The electrophysiological net
1124 response ('F-complex') to spatial fusion of speech elements
1125 forming an auditory object. *Clin Neurophysiol* **114**, 818-834.
- 1126 [71] Mulert C, Gallinat J, Pascual-Marqui R, Dorn H, Frick K,
1127 Schlattmann P, Mientus S, Herrmann WM, Winterer G (2001)
1128 Reduced event-related current density in the anterior cingulate
1129 cortex in schizophrenia. *Neuroimage* **13**(4), 589-600.
- 1130 [72] Klimesch W. (1996) Memory processes, brain oscillations and
1131 EEG synchronization. *Int J Psychophysiol* **24**, 61-100.
- 1132 [73] Leuchter AF, Cook IA, Newton TF, Dunkin J, Walter DO,
1133 Rosenberg Tompson S, Lachenbruch PA, Weiner H (1993)
1134 Regional differences in brain electrical activity in dementia:
use of spectral power and spectral ratio measures. *Electroen-
ceph clin Neurophysiol* **87**, 385-393.
- [74] Nuwer MR (1988) Quantitative EEG. I: techniques and prob-
lems of frequency analysis and topographic mapping. *J Clin
Neurophysiol* **5**, 1-43.
- [75] Hern, aacute, ndez JL, Vald, eacute, s P, Biscay R, Viru,
eacute, s T, Szava S, Bosch J, Riquenes A, Clark I (1994) A
global scale factor in brain topography. *Int J Neurosci* **76**, 267-
278.
- [76] Prichep LS, John ER, Ferris SH, Reisberg B, Almas M, Alper
K, Cancro R (1994) Quantitative EEG correlates of cognitive
deterioration in the elderly. *Neurobiol Aging* **15**, 85-90.
- [77] Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO
(2003) A critical discussion of the role of neuroimaging in
mild cognitive impairment. *Acta Neurol Scand* **107**, 52-76.
- [78] Moretti DV, Babiloni C, Binetti G, Cassetta E, Dal Forno G,
Ferreri F, Ferri R, Lanuzza B, Miniussi C, Nobili F, Rodriguez
G, Salinari S, Rossini PM (2004) Individual analysis of EEG
frequency and band power in mild Alzheimer's Disease. *Clin
Neurophysiol* **115**, 299-308.
- [79] Steriade M (2003) Cerebello-cerebral interactions during
states of vigilance. *Cerebellum* **2**, 82-83.
- [80] Steriade M (1996) Awakening the brain. *Nature* **383**, 24-25.
- [81] Klimesch W, Doppelmayr M, Pachinger T, Russegger H
(1997) Event-related desynchronization in the alpha band and
the processing of semantic information. *Brain Res Cogn Brain
Res* **6**, 83-94.
- [82] Klimesch W, Doppelmayr M, Russegger H, Pachinger T,
Schwaiger J (1998) Induced alpha band power changes in
the human EEG and attention. *Neurosci Lett* **244**, 73-76.
- [83] Rossini PM, Desiato MT, Lavaroni F, Caramia MD (1991)
Brain excitability and electroencephalographic activation:
non-invasive evaluation in healthy humans via transcranial
magnetic stimulation. *Brain Res* **13**, 111-119.
- [84] Steriade M, Llinás RR (1988) The functional states of the
thalamus and the associated neuronal interplay. *Physiol Rev*
68, 649-742.
- [85] Ricceri L, Minghetti L, Moles A, Popoli P, Confaloni A, De
Simone R, Piscopo P, Scattoni ML, Di Luca M, Calamandrei
G (2004) Cognitive and neurological deficits induced by early
and prolonged basal forebrain cholinergic hypofunction in
rats. *Exp Neurol* **189**, 162-172.
- [86] Braak H, Braak E (1996) Evolution of the neuropathology of
Alzheimer's disease. *Acta Neurol Scand Suppl* **165**, 3-12.
- [87] Braak H, Braak E (1998) Evolution of neuronal changes in
the course of Alzheimer's disease. *J Neural Transm Suppl* **53**,
127-140.
- [88] Regan C, Katona C, Walker Z, Hooper J, Donovan J,
Livingston G (2006) Relationship of vascular risk to the pro-
gression of Alzheimer disease. *Neurology* **67**, 1357-1362.
- [89] Etiene D, Kraft J, Ganju N, Gomez-Isla T, Gemelli B, Hyman
BT, Hedley-Whyte ET, Wands JR, De La Monte SM (1998)
Cerebrovascular pathology contributes to the heterogeneity
of Alzheimer's disease. *J Alzheimers Dis* **1**, 119-134.
- [90] Heyman A, Fillenbaum GG, Welsh-Bohmer KA, Gearing M,
Mirra SS, Mohs RC, Peterson BL, Pieper CF (1998) Cerebral
infarcts in patients with autopsy-proven Alzheimer's disease:
CERAD, part XVIII. Consortium to Establish a Registry for
Alzheimer's Disease. *Neurology* **51**, 159-162. Erratum in:
Neurology **51**, 1809.
- [91] Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD (1999)
Cerebrovascular disease and threshold for dementia in the
early stages of Alzheimer's disease. *Lancet* **354**, 919-920.
- [92] Lee JH, Olichney JM, Hansen LA, Hofstetter CR, Thal LJ
(2000) Small concomitant vascular lesions do not influence

- 1200 rates of cognitive decline in patients with Alzheimer disease. 1215
1201 *Arch Neurol* **57**, 1474-1479. 1216
- 1202 [93] Jellinger KA (2001) Small concomitant cerebrovascular 1217
1203 lesions are not important for cognitive decline in severe 1218
1204 Alzheimer disease (letter). *Arch Neurol* **58**, 520-521. 1219
- 1205 [94] Mungas D, Reed BR, Ellis WG, Jagust WJ (2001) The effects 1220
1206 of age on rate of progression of Alzheimer disease and demen- 1221
1207 tia with associated cerebrovascular disease. *Arch Neurol* **58**, 1222
1208 1243-1247. 1223
- 1209 [95] Brown WR, Thore CR (2011) Cerebral microvascular pathol- 1224
1210 ogy in ageing and neurodegeneration. *Neuropathol Appl 1225*
1211 *Neurobiol* **37**, 56-74. 1226
- 1212 [96] Balthazar ML, Yasuda CL, Pereira FR, Pedro T, Damasceno 1227
1213 BP, Cendes F Differences in grey and white matter atrophy 1228
1214 in amnesic mild cognitive impairment and mild Alzheimer's 1229
1230 disease. *Eur J Neurol* **16**, 468-474. 1231
- [97] Serra L, Cercignani M, Lenzi D, Perri R, Fadda L, Calta- 1215
1216 girone C, Macaluso E, Bozzali M (2010) Grey and white 1217
1218 matter changes at different stages of Alzheimer's disease. *J 1219*
1220 *Alzheimers Dis* **19**, 147-159. 1221
- [98] Teipel SJ, Meindl T, Grinberg L, Grothe M, Cantero JL, 1222
1223 Reiser MF, ouml M, Iler HJ, Heinsen H, Hampel H (2011) 1224
1225 The cholinergic system in mild cognitive impairment and 1226
1227 Alzheimer's disease. An in vivo MRI and DTI study. *Hum 1228*
1229 *Brain Mapp*. doi:10.1002/hbm.21111. 1230
- [99] . Teipel SJ, Meindl T, Wagner M, Stieltjes B, Reuter S, Hauen- 1231
1232 stein KH, Filippi M, Ernemann U, Reiser MF, Hampel H. 1233
1234 Longitudinal Changes in Fiber Tract Integrity in Healthy 1235
1236 Aging and Mild Cognitive Impairment: A DTI Follow-Up 1237
1238 Study. *J Alzheimers Dis* **22,2**, 507-522. 1239

Uncorrected Author